Researchers in Chicago have conducted a phase I/II trial of autologous non-myeloablative hematopoietic stem cell transplantation (SCT) in 21 relapsing-remitting MS patients (Burt et al. Lancet Neurol 2009; epublished January 29, 2009). All subjects had experienced >2 steroid-treated relapses or 1 relapse with Gd-enhancing lesions in the previous 12 months despite treatment with a beta-interferon. Subscribe to read more It takes 30 seconds or logi…

…For multiple sclerosis patients who fail to respond to a first-line disease-modifying treatment (DMT), switching to another DMT is a generally effective strategy, according to an analysis by U.S. and Italian researchers (Gajofatto et al. Mult Scler 2009;15:50-58). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…